Reported results
- Net loss attributable to common stockholders was $1.234 million, or $0.34 basic and diluted net loss per share, for the three months ended September 30, 2026, compared to $0.877 million, or $0.24 basic and diluted net loss per share, for the three months ended September 30, 2025.
- General and administrative expenses were $1.220 million for the three months ended September 30, 2026, compared to $0.858 million for the three months ended September 30, 2025.
- Research and development expenses were $1 thousand (less than $0.1 million) for the three months ended September 30, 2026, compared to $8 thousand for the three months ended September 30, 2025.
- Cash and cash equivalents balance as of September 30, 2026, was $1.398 million, compared to $4.088 million as of December 31, 2025.
- Restricted cash balance as of September 30, 2026, was $700 thousand.
Notes
The Company’s unaudited financial statements were prepared assuming that the Company will continue as a going concern within one year after the date such financial statements are issued.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-17 (8-K, Item 2.02). Read the original filing on sec.gov.
